BoveRChitnisT. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler. 2014Feb25. [Epub ahead of print].
2.
MillerDHFazekasFMontalbanXReingoldSCTrojanoM. Pregnancy, sex and hormonal factors in multiple sclerosis. Mult Scler2014Jan20. [Epub ahead of print] PubMed PMID: 24446387
3.
WeinshenkerBGBassBRiceGP. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain1989; 112: 133–146.
4.
ConfavreuxCVukusicS.Natural history of multiple sclerosis: A unifying concept. Brain2006; 129: 606–616.
5.
TremlettHPatyDDevonshireV.Disability progression in multiple sclerosis is slower than previously reported. Neurology2006; 66: 172–177.
6.
ScalfariANeuhausADegenhardtA. The natural history of multiple sclerosis: A geographically based study 10: Relapses and long-term disability. Brain2010; 133: 1914–1929.
7.
TintoreMRoviraARioJ. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology2006; 67: 968–972.
8.
FisnikuLKBrexPAAltmannDR. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain2008; 131: 808–817.
9.
ComiGDe StefanoNFreedmanMS. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): A phase 3 randomised controlled trial. Lancet Neurol2012; 11: 33–41.
10.
ComiGFilippiMBarkhofF. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet2001; 357: 1576–1582.
11.
KapposLPolmanCHFreedmanMS. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology2006; 67: 1242–1249.
12.
JacobsLDBeckRWSimonJH. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med2000; 343: 898–904.
